Vanguard Global Advisers
LPCN icon

Vanguard Global Advisers’s Lipocine LPCN Stock Holding History

Vanguard Global Advisers’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33K Hold
1,691
– – ﹤0.01% 3563
2026
Q1 		$13.5K Buy
+1,691
New +$14.7K ﹤0.01% 3428

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's LPCN Position: Q2 2026 in Review

Vanguard Global Advisers held its Lipocine (LPCN) position steady in Q2 2026 at 1,691 shares worth $4.33K. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

Vanguard Global Advisers first reported a position in LPCN in Q1 2026 and has held it in 2 quarters since. The position peaked at $13.5K in Q1 2026. 34 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Vanguard Global Advisers held 1,691 shares of Lipocine worth $4.33K as of Q2 2026.
  • Vanguard Global Advisers left its Lipocine share count unchanged in Q2 2026.
  • Lipocine made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3563 holding.
  • Vanguard Global Advisers first reported a position in Lipocine in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Lipocine position peaked at $13.5K in Q1 2026.
  • 34 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.